Sangamo Appoints CEO
Executive Summary
Sangamo Biosciences, a company focused on treating monogenic and infectious diseases using its DNA-binding protein technology, has appointed Alexander 'Sandy' Macrae president and CEO. Macrae will be succeeding current president and CEO Edward Lanphier, who will be retiring from his leadership position but will continue as board member. Macrae previously held roles of increasing responsibility at SmithKline Beecham and GlaxoSmithKline, where his last role was senior vice president, emerging markets research and development.
You may also be interested in...
Pipeline Watch: Six Approvals And 15 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Three New CMOs And CFOs Among This Week's Changes
Recent moves in the industry include C-suite shuffles at PureTech Health and Traws Pharma, plus Xencor gets a new chief financial officer.
Pipeline Watch: Six Approvals And Nine Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.